To provide updated, evidence-based recommendations for the diagnosis and assessment of adults with hypertension.
H ypertension affects 27% of the Canadian adult population 35 to 64 years of age (1) , and remains one of the most common modifiable risk factors for cardiovascular disease in Canada and globally (2, 3) . The present document summarizes the 2009 Canadian Hypertension Education Program (CHEP) recommendations for the diagnosis and assessment of hypertension in adults, focusing on those recommendations that are new or updated. For issues related to the diagnosis and evaluation of high blood pressure in children and adolescents, the reader is referred to separate guidelines (4) . A more detailed discussion of previous changes to the Canadian recommendations is available in previous publications (5) (6) (7) (8) . Summary documents of all recommendations, including downloadable slide kits, are available free of charge on the Canadian Hypertension Society Web site (www.hypertension.ca).
mETHOdS
The previously published methodology remains unchanged (9) and was previously described (10) . In brief, grade A recommendations are based on studies with high levels of internal validity, statistical precision, generalizability and clinical relevance. Grade B and C recommendations are derived from studies characterized by lower internal validity, precision or generalizability, or from studies reporting intermediate or surrogate outcomes instead of more clinically relevant ones. Grade D recommendations are based on expert opinion or studies with lower levels of internal validity or precision than grade C recommendations.
THE 2009 CHEP RECOmmENdATIONS
I. Accurate measurement of blood pressure Recommendations 1) Health care professionals who have been specifically trained to measure blood pressure (BP) accurately should assess BP in all adult patients at all appropriate visits to determine cardiovascular risk and monitor antihypertensive treatment (grade D). 2) Use of standardized measurement techniques (Table 1) is recommended when assessing blood pressure (grade D).
Background
There have been no changes to these recommendations in 2009.
II. Criteria for diagnosis of hypertension and recommendations for follow-up (Figure 1)
Recommendations 1) At initial presentation, patients demonstrating features of a hypertensive urgency or emergency (Table 2) should be diagnosed as hypertensive and require immediate management (grade D). 2) If systolic BP (SBP) is 140 mmHg or higher and/or diastolic BP (DBP) is 90 mmHg or higher, a specific visit should be scheduled for the assessment of hypertension (grade D). If BP is high normal (SBP 130 mmHg to 139 mmHg and/or DBP 85 mmHg to 89 mmHg), annual follow-up is recommended (grade C).
3) At the initial visit for the assessment of hypertension, if SBP is 140 mmHg or higher and/or DBP is 90 mmHg or higher, at least two more readings should be taken during the same visit using a validated device and according to the recommended procedure for accurate BP determination ( Table 1 ). The first reading should be discarded and the latter two averaged. A history and physical examination should be performed and, if clinically indicated, diagnostic tests to search for target organ damage (Table 3) and associated cardiovascular risk factors (Table 4) should be arranged within two visits. Exogenous factors that can induce or aggravate hypertension should be assessed and removed if possible ( 
Background
The criteria for the diagnosis of hypertension were previously discussed in detail (11) . It should be emphasized that when using office BPs to diagnose hypertension, the thresholds given above refer to readings averaged over the specified number of visits and not just on the last visit.
III. Assessment of overall cardiovascular risk in hypertensive patients
Recommendations 1) Global cardiovascular risk should be assessed. Multifactorial risk assessment models can be used to predict more accurately an individual's global cardiovascular risk (grade A) and to use antihypertensive therapy more efficiently (grade D). In the absence of Canadian data to determine the accuracy of risk calculations, avoid using absolute levels of risk to support treatment decisions (grade C). 2) Consider informing patients of their global risk to improve the effectiveness of risk factor modification (grade C).
Background
Recognizing the importance of global risk assessment as a component of hypertension therapy (12) (20, 21) and the Symptoms-CausesOutput-Resources-Effects (SCORE) model (www.scorecanada.ca) (22) . Measurement of the ankle-brachial index may improve the accuracy of cardiovascular risk prediction beyond risk scoring alone (23) . Detailed guidelines for hypertension treatment based on absolute risk thresholds are not available at this time, given the lack of published studies examining the validity of these models in the Canadian population. However, global risk assessment in general, and the use of these models specifically, can be used as a tool to assist physicians in identifying subjects with hypertension who are most likely to benefit from therapy. When considering an individual's future risk of developing cardiovascular disease and the potential impact of antihypertensive therapy, one should consider assessing both the risk of future cardiac as well as cerebrovascular events (24) .
A recently published randomized clinical trial among Canadians with dyslipidemia has demonstrated that explicitly calculating a patient's cardiovascular risk and discussing the results can significantly increase the likelihood of achieving lipid targets, even after adjustment for the intensity of statin therapy (25) . This suggests that informed patients are more adherent to lifestyle recommendations and/or pharmacotherapy. Although a similar trial focusing on hypertensive management has not been completed, these results are potentially generalizable to individuals with hypertension. ii) Choose a cuff with an appropriate bladder size matched to the size of the arm. For measurements taken by auscultation, bladder width should be close to 40% of arm circumference and bladder length should cover 80% to 100% of arm circumference. When using an automated device, select the cuff size as recommended by its manufacturer.
IV. Routine and optional laboratory tests for the investigation of patients with hypertension
iii) Place the cuff so that the lower edge is 3 cm above the elbow crease and the bladder is centred over the brachial artery. The patient should be resting comfortably for 5 min in the seated position with back support. The arm should be bare and supported with the blood pressure cuff at heart level, because a lower position will result in an erroneously higher systolic blood pressure and diastolic blood pressure. There should be no talking, and patients' legs should not be crossed. At least three measurements should be taken in the same arm with the patient in the same position. The first reading should be discarded and the latter two averaged. Blood pressure also should be assessed after 2 min standing (with arm supported) and at times when patients report symptoms suggestive of postural hypotension. Supine blood pressure measurements may also be helpful in the assessment of elderly and diabetic patients.
iv) Increase the pressure rapidly to 30 mmHg above the level at which the radial pulse is extinguished (to exclude the possibility of a systolic auscultatory gap).
v) Place the bell or diaphragm of the stethoscope gently and steadily over the brachial artery.
vi) Open the control valve so that the rate of deflation of the cuff is approximately 2 mmHg per heart beat. A cuff deflation rate of 2 mmHg per beat is necessary for accurate systolic and diastolic estimation. vii) Read the systolic level -the first appearance of a clear tapping sound (phase I Korotkoff) -and the diastolic level (the point at which the sounds disappear) (phase V Korotkoff). Continue to auscultate at least 10 mmHg below phase V to exclude a diastolic auscultatory gap. Record the blood pressure to the closest 2 mmHg on the manometer (or 1 mmHg on electronic devices), the arm used and whether the patient was supine, sitting or standing. Avoid digit preference by not rounding up or down. Record the heart rate. The seated blood pressure is used to determine and monitor treatment decisions. The standing blood pressure is used to examine for postural hypotension, if present, which may modify the treatment.
viii) If Korotkoff sounds persist as the level approaches 0 mmHg, then the point of muffling of the sound is used (phase IV) to indicate the diastolic pressure.
ix) In the case of arrhythmia, additional readings may be required to estimate the average systolic and diastolic pressure. Isolated extra beats should be ignored. Note the rhythm and pulse rate.
x) Leaving the cuff partially inflated for too long will fill the venous system and make the sounds difficult to hear. To avoid venous congestion, it is recommended that at least 1 min should elapse between readings.
xi) Blood pressure should be taken in both arms on at least one visit and if one arm has a consistently higher pressure, that arm should be subsequently used for blood pressure measurement and interpretation. 
Background
As previously discussed, the routine ascertainment of microalbuminuria in all nondiabetic hypertensive patients is currently not recommended (5). However, assessment for microalbuminuria may be indicated in selected patients when a global risk assessment is being performed to identify high-risk hypertensive patients eligible for statin therapy (6, 26) . Assessment of microalbuminuria is also required to guide therapy in patients with diabetes and those with chronic kidney disease. Monitoring all hypertensive patients for incident diabetes according to the recommendations outlined in the guidelines of the 
Figure 1) The expedited assessment and diagnosis of patients with hypertension (HTN): focus on validated technologies for blood pressure (BP) assessment. *Thresholds refer to BP values averaged across the corresponding number of visits, and not just the most recent office visit. ABPM Ambulatory BP monitoring; BPM BP monitoring; DBP Diastolic BP; SBP Systolic BP. Reprinted with permission from the Canadian Hypertension Education Program
Canadian Diabetes Association (www.diabetes.ca) is recommended. In part, hypertensive patients are at higher risk for developing type 2 diabetes because of the tendency of cardiometabolic risk factors to cluster, particularly in the presence of central adiposity (27) (28) (29) . At minimum, new-onset diabetes occurs in 1% to 2% of hypertensive patients each year (30, 31) . Among 18,411 nondiabetic hypertensive patients older than 55 years of age who had follow-up measurements of fasting plasma glucose (43% of the original cohort), the cumulative incidence of diabetes was 8% to 11% at four years (32) . Furthermore, the prognosis of patients who develop diabetes is worse than those who do not (30) (31) (32) (33) (34) Although based on weaker evidence, the type of antihypertensive drug treatment also appears to influence future risk of type 2 diabetes (27, 28) . Studies suggest that both beta-blockers and thiazides are associated with an increased risk of diabetes, and angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers are neutral or associated with decreased risk (27) . However, in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial (35) (three-year randomized controlled trial involving 5269 prediabetic patients), ramipril did not significantly reduce the incidence of type 2 diabetes (HR 0.91, 95% CI 0.81 to 1.03) or mortality. Thus, no specific antihypertensive drugs are currently recommended to prevent the development of diabetes mellitus.
It is important to note that there are currently no conclusive data that directly implicate drug-induced type 2 diabetes with increased cardiovascular risk (33) . Furthermore, in patients with or without diabetes, thiazide-based treatment regimens reduce cardiovascular and overall mortality to a similar extent as 'nondiabetogenic' agents (6). The task force will continue to monitor this area closely and issue updated recommendations as required. 
V. Assessment for renovascular hypertension
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v) other atherosclerotic vascular disease, particularly in patients who smoke or have dyslipidemia; and vi) recurrent pulmonary edema associated with hypertensive surges. 2) When available, the following tests are recommended to aid in the usual screening for renal vascular disease: captopril-enhanced radioisotope renal scan, Doppler sonography, magnetic resonance angiography and computed tomographic angiography (for those with normal renal function) (grade B). Captopril-enhanced radioisotope renal scan is not recommended for those with CKD (GFR less than 60 mL/min) (grade D).
Background
There are no changes from the 2008 recommendations (7). Most diagnostic testing for renovascular hypertension has been validated in patients with normal renal function. In patients with CKD, there are notable limitations to current screening methods and the optimal method is uncertain. The diagnostic accuracy of captopril renal scanning is poor in the setting of GFR levels below 60 mL/min (36) . Nephrogenic systemic fibrosis may very rarely occur (estimated incidence one per million) in patients receiving gadolinium-based contrast media for magnetic resonance angiography. The risk may vary by contrast agent and is higher in patients with CKD (particularly those with end-stage renal failure); similarly, computed tomographic angiography carries a risk of contrast nephropathy (37) . Duplex Doppler ultrasonography of the renal vessels is safe, but is highly specialized, operator-dependent and not widely available (38) .
VI. Endocrine hypertension Recommendations
A. Hyperaldosteronism -screening and diagnosis 1. Screening for hyperaldosteronism should be considered for the following patients (grade D): i) hypertensive patients with spontaneous hypokalemia (K + level lower than 3.5 mmol/L);
ii) hypertensive patients with marked diuretic-induced hypokalemia (K + level lower than 3.0 mmol/L); iii) patients with hypertension refractory to treatment with three or more drugs; and iv) hypertensive patients found to have an incidental adrenal adenoma. 2. Screening for hyperaldosteronism should include assessment of plasma aldosterone and plasma renin activity (Table 6) . 3. For patients with suspected hyperaldosteronism (on the basis of the screening test, Table 6 [iii]), a diagnosis of primary aldosteronism should be established by demonstrating inappropriate autonomous hyper secretion of aldosterone using at least one of the manoeuvres listed in Table 6 (iv). When the diagnosis is established, the abnormality should be localized using any of the tests described in Table 6 (v).
B. Pheochromocytoma -screening and diagnosis 1. If pheochromocytoma is strongly suspected, the patient should be referred to a specialized hypertension centre, particularly if biochemical screening tests (Table 7) have already been found to be positive (grade D). 2. The following patients should be considered for screening for pheochromocytoma (grade D): i) patients with paroxysmal and/or severe (BP 180/110 mmHg or higher) sustained hypertension refractory to usual antihypertensive therapy; ii) patients with hypertension and multiple symptoms suggestive of catecholamine excess (eg, headaches, palpitations, sweating, panic attacks and pallor); iii) patients with hypertension triggered by beta-blockers, monoamine oxidase inhibitors, micturition or changes in abdominal pressure; and iv) patients with incidentally discovered adrenal masses, patients with hypertension and multiple endocrine neoplasia 2A or 2B, iii) Definition of a positive screening test: plasma aldosterone to renin activity ratio greater than 550 pmol/L/ng/mL/h (or 140 pmol/L/ng/L when renin is measured as renin mass or concentration).
iv) Manoeuvres to demonstrate autonomous hypersecretion of aldosterone: ii) symptoms suggestive of hypotension (grade C); or iii) fluctuating office BP readings (grade D). 3) Physicians should use only ABPM devices that have been validated independently using established protocols (grade D). 4) Therapy adjustment should be considered in patients with a 24 h ambulatory SBP of 130 mmHg or higher or DBP of 80 mmHg or higher, or an awake SBP of 135 mmHg or higher or DBP of 85 mmHg or higher (grade D). 5) The magnitude of changes in nocturnal BP should be taken into account in any decision to prescribe or withhold drug therapy based on ambulatory BP (grade C) because a decrease in nocturnal blood pressure of less than 10% is associated with increased risk of cardiovascular events.
Background
There are no new recommendations in this section. 
IX. Role of echocardiography
FuTuRE dIRECTIONS
The CHEP Recommendations Task Force will continue to monitor the published literature and update these guidelines annually based on new developments in the literature and feedback from stakeholders and other users of these recommendations. 
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